Log In
BCIQ
Print this Print this
 

Proxinium (VB4-847)

  Manage Alerts
Collapse Summary General Information
Company Eleven Biotherapeutics Inc.
DescriptionTumor targeting antibody fragment conjugated with Pseudomonas exotoxin A
Molecular Target Epithelial cell adhesion molecule (EpCAM)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationHead and neck cancer
Indication DetailsTreat advanced head and neck cancer; Treat advanced, recurrent head and neck cancer; Treat recurrent squamous cell carcinoma of the head and neck (SCCHN); Treat refractory head and neck cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$36.0M

0

$22.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/21/2016

$36.0M

0

$22.5M

Get a free BioCentury trial today